Dr Christian Aloe is a Research Fellow in the Centre for Respiratory Science and Health (CRSH) at RMIT University. He is supervised by Professor Steven Bozinovski.
Follow Christian on LinkedIn.
Tell us a bit about yourself and how you got interested in pulmonary fibrosis research.
Early in my training I worked in lung cancer research, which sparked a broader interest in how inflammation and the tissue environment influence disease progression. I later focused on tissue repair and remodelling during my PhD, where I became increasingly interested in fibrosis as a consequence of dysregulated healing.
This naturally led me into pulmonary fibrosis research, where I now focus on uncovering the biological changes that shape disease progression and how they might inform more targeted therapeutic strategies.
How would you explain your pulmonary fibrosis research to someone unfamiliar with the field?
My research explores how immune cells in the lung respond to stress and injury, and how these responses can shift from supporting normal tissue repair toward driving fibrotic remodelling. My work is anchored in occupational lung diseases such as silicosis, where inhaled particles trigger persistent inflammation and progressive fibrosis. I am particularly interested in macrophages, which play a central role in maintaining lung homeostasis, and how distinct populations may adopt divergent functional behaviours during disease.
Across different forms of lung fibrosis, emerging evidence points to shared biological features linked to metabolically stressed immune cells that may contribute to disease progression. By investigating these patterns, my work aims to better define the early biological changes that shape fibrosis, and to uncover biological signals that could inform future therapeutic strategies.
Why is this work important?
Pulmonary fibrosis is often diagnosed once significant lung damage has already occurred, leaving limited opportunities to change the course of disease. This is especially relevant in conditions such as silicosis, where harmful exposures may happen years before symptoms appear. By focusing on early biological signals and how immune cells respond to injury, my research aims to improve how we recognise disease activity and better understand the processes driving progression. Strengthening this link between biological insight and clinical understanding could ultimately help preserve lung function and improve quality of life for people living with fibrotic lung disease.
What are some of your biggest achievements to date?
Through collaborative work within Professor Bozinovski’s program and the broader CRE-PF network, I have contributed to one of the earliest human transcriptomic analyses of silicosis using patient bronchoalveolar lavage samples, helping to characterise immune cell stress pathways and lipid-associated macrophage features that may influence fibrotic progression across interstitial lung diseases.
These research efforts have been strengthened through a 2025 CREATE Hope Fellowship in Pulmonary Fibrosis Research, and through the co-development of a successful CREATE Grant-in-Aid. Together, these initiatives have expanded collaboration across the CRE-PF network and enabled deeper investigation of macrophage dysfunction, shaping new experimental and therapeutic avenues.
What are the best bits about working in this area?
One of the best parts of working in pulmonary fibrosis research is being part of a community that is genuinely motivated to improve outcomes for people living with lung disease. The field brings together different perspectives, from discovery science through to patient experience, which helps keep the research grounded in real-world challenges. It feels like we’re at a really interesting stage where new biological insights are beginning to reshape how fibrotic lung disease is understood, and that sense of momentum makes the work especially rewarding.
Where do you hope to see yourself in your career in the next five years? Are there any shifts you would like to see in the field during that time?
Over the next five years, I’d like to continue focusing on the early biological changes that shape fibrosis progression and how these insights relate to patient outcomes. I’m particularly interested in approaches that help bridge detailed molecular research with clinical information, allowing us to better understand patterns of disease progression over time.
More broadly, I would love to see the field continue building on the strong progress already being made toward earlier recognition of disease and a deeper understanding of fibrotic lung disease. Ongoing collaboration between researchers, clinicians and patient communities will remain central as new biological insights begin to complement and support existing clinical expertise.